Literature DB >> 29960607

Frequent Adverse Drug Reactions, and Medication Groups under Suspicion.

Diana Dubrall1, Matthias Schmid, Eva Alešik, Norbert Paeschke, Julia Stingl, Bernhardt Sachs.   

Abstract

BACKGROUND: The adverse drug reaction database of the German Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) contains reports of suspected adverse drug reactions (ADRs) that are spon- taneously submitted by physicians, pharmacists, or patients. The aim of the present study was a descriptive analysis of all of these spontaneous reports.
METHODS: 345 662 spontaneously submitted reports were analyzed with respect to the number of reports per year, the sources of the reports, demographic variables, the most commonly reported ADRs, and the drug classes most commonly suspected.
RESULTS: The number of reports submitted spontaneously each year has grown steadily since 1978. At the least detailed level of analysis, "drugs for the treatment of nervous system disorders" were the most common class of drugs under suspicion of causing the reported adverse drug reactions (23.1%). In a more detailed analysis by therapeutic subgroup, the three subgroups most commonly reported as suspected of causing side effects were antithrombotic agents, systemic antibiotics, and psycholeptics-causing thrombocytopenia, diarrhea, and drug dependency as the most frequently reported ADRs, respectively. The order of drug classes most commonly causing ADRs differed markedly between the physicians' reports (diazepines, fluoroquinolones, heparins) and the patients' reports (interferons, anti- thrombotic drugs, selective immunosuppressant drugs). Patients more commonly reported subjectively perceived ADRs, while physicians more commonly reported findings or diagnoses that require medical expertise.
CONCLUSION: The increasing number of spontaneous reports is mainly due to reports forwarded from pharmaceutical companies to the BfArM. This, in turn, is probably a result of increasingly strict legal reporting requirements in Germany. The detected differences between physicians' and patients' ADR reports can be taken to indicate that patients should be more specifically informed and questioned about potential ADRs. By reporting adverse drug reactions, physicians may improve drug safety.

Entities:  

Mesh:

Year:  2018        PMID: 29960607      PMCID: PMC6041966          DOI: 10.3238/arztebl.2018.0393

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  20 in total

1.  Why there is a need for pharmacovigilance.

Authors:  W K Amery
Journal:  Pharmacoepidemiol Drug Saf       Date:  1999-01       Impact factor: 2.890

2.  Big Data and Adverse Drug Reaction Detection.

Authors:  R Harpaz; W DuMochel; N H Shah
Journal:  Clin Pharmacol Ther       Date:  2015-12-23       Impact factor: 6.875

Review 3.  Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications.

Authors:  A Hämmerlein; H Derendorf; D T Lowenthal
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

4.  A description of signals during the first 18 months of the EMA pharmacovigilance risk assessment committee.

Authors:  Alexandra C Pacurariu; Preciosa M Coloma; Anja van Haren; Georgy Genov; Miriam C J M Sturkenboom; Sabine M J M Straus
Journal:  Drug Saf       Date:  2014-12       Impact factor: 5.606

5.  Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.

Authors:  Lise Aagaard; Johanna Strandell; Lars Melskens; Paw S G Petersen; Ebba Holme Hansen
Journal:  Drug Saf       Date:  2012-12-01       Impact factor: 5.606

6.  Is spontaneous reporting always the most important information supporting drug withdrawals for pharmacovigilance reasons in France?

Authors:  Marie-Noelle Paludetto; Pascale Olivier-Abbal; Jean-Louis Montastruc
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-09-07       Impact factor: 2.890

Review 7.  Postmarketing safety surveillance : where does signal detection using electronic healthcare records fit into the big picture?

Authors:  Preciosa M Coloma; Gianluca Trifirò; Vaishali Patadia; Miriam Sturkenboom
Journal:  Drug Saf       Date:  2013-03       Impact factor: 5.606

8.  Gender-based differences in drug prescription: relation to adverse drug reactions.

Authors:  Y Zopf; C Rabe; A Neubert; C Janson; K Brune; E G Hahn; H Dormann
Journal:  Pharmacology       Date:  2009-10-17       Impact factor: 2.547

9.  Adverse Drug Reaction Reporting Pattern in Turkey: Analysis of the National Database in the Context of the First Pharmacovigilance Legislation.

Authors:  Gulnihal Ozcan; Emel Aykac; Yelda Kasap; Nergiz T Nemutlu; Ebru Sen; N Demet Aydinkarahaliloglu
Journal:  Drugs Real World Outcomes       Date:  2016-03

Review 10.  A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting.

Authors:  Tariq M Alhawassi; Ines Krass; Beata V Bajorek; Lisa G Pont
Journal:  Clin Interv Aging       Date:  2014-12-01       Impact factor: 4.458

View more
  16 in total

1.  In Reply.

Authors:  Diana Dubrall; Bernhardt Sachs
Journal:  Dtsch Arztebl Int       Date:  2018-10-12       Impact factor: 5.594

2.  Unanswered Questions.

Authors:  Burger Lichtenstein
Journal:  Dtsch Arztebl Int       Date:  2018-10-12       Impact factor: 5.594

3.  In Reply.

Authors:  Julia C Stingl; Harald Dormann; FirstName MiddleName LastName
Journal:  Dtsch Arztebl Int       Date:  2018-09-03       Impact factor: 5.594

Review 4.  Psychopharmacological Treatment in Older People: Avoiding Drug Interactions and Polypharmacy.

Authors:  Torsten Kratz; Albert Diefenbacher
Journal:  Dtsch Arztebl Int       Date:  2019-07-22       Impact factor: 5.594

5.  A Comparative Safety Analysis of Medicines Based on the UK Pharmacovigilance and General Practice Prescribing Data in England.

Authors:  Kinan Mokbel; Rob Daniels; Michael N Weedon; Leigh Jackson
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

6.  The heterogeneous pharmacological medical biochemical network PharMeBINet.

Authors:  Cassandra Königs; Marcel Friedrichs; Theresa Dietrich
Journal:  Sci Data       Date:  2022-07-11       Impact factor: 8.501

7.  Improving drug safety in hospitals: a retrospective study on the potential of adverse drug events coded in routine data.

Authors:  Nils Kuklik; Jürgen Stausberg; Marjan Amiri; Karl-Heinz Jöckel
Journal:  BMC Health Serv Res       Date:  2019-08-08       Impact factor: 2.655

8.  Adverse drug reactions in older adults: a retrospective comparative analysis of spontaneous reports to the German Federal Institute for Drugs and Medical Devices.

Authors:  Diana Dubrall; Katja S Just; Matthias Schmid; Julia C Stingl; Bernhardt Sachs
Journal:  BMC Pharmacol Toxicol       Date:  2020-03-23       Impact factor: 2.483

9.  [Recommendations of the second update of the LONTS guidelines : Long-term opioid therapy for chronic noncancer pain].

Authors:  Winfried Häuser; Frietjof Bock; Michael Hüppe; Monika Nothacker; Heike Norda; Lukas Radbruch; Marcus Schiltenwolf; Matthias Schuler; Thomas Tölle; Annika Viniol; Frank Petzke
Journal:  Schmerz       Date:  2020-06       Impact factor: 1.107

10.  Angioedemas associated with renin-angiotensin system blocking drugs: Comparative analysis of spontaneous adverse drug reaction reports.

Authors:  Diana Dubrall; Matthias Schmid; Julia Carolin Stingl; Bernhardt Sachs
Journal:  PLoS One       Date:  2020-03-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.